BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader that combines cutting-edge Artificial Intelligence (AI) and science to accelerate biopharma discovery and development, today announced a strategic review approved by its Board of Directors. BenevolentAI is further evolving its differentiated technology platform and launching a new suite of products to capitalise on the vast potential of AI-driven technologies in the biopharma domain. Simultaneously, the Company is optimising its portfolio to focus on its most...